Oral presentations

8. Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions.
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec – October 19th-21st, 2017 (Ottawa, Canada.)
7. Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions.
Journée Phare 2016 – December 1st-2nd, 2016 (Bromont, Canada.)
6. Phosphomimetic lipopeptides as new tools to investigate β-arrestin-mediated functions.
Neuroscience 2016 – 46th Annual Meeting of the Society for Neuroscience – November 12th-16th, 2016 (San Diego, USA.)
5. β-arrestin-2-biased apelin receptor agonists as novel potent analgesics.
Symposium of the Pain and Inflammation research axis of the Université de Sherbrooke – November 2nd, 2016 (Sherbrooke, Canada.)
4. New biased analogs of Apelin-13 and their impacts on cardiovascular effects.
5th Montpellier-Sherbrooke Symposium – June 11th, 2015 (Sherbrooke, Canada.)
3. Molecular Signature of the Neurotensin Receptor 1.
3rd Scientific day of Quebec Drug Research Network – September 18th-19th, 2013 (Montreal, Canada)
2. BRET-Based Assay Development for the Discovery of Novel GPCR Ligands.
Journée Phare 2012 – November 16th, 2012 (Orford, Canada)
1. BRET-Based Assay Development for the Discovery of Novel GPCR Ligands.
Conference of the Sherbrooke Institute of Pharmacology – October 25th, 2012 (Sherbrooke, Canada)

Poster presentations at international conferences

(* denotes presenting author)

47. Tiffinger A., *Besserer-Offroy É., Côté J., Coquerel D., Murza A., Longpré J.M., Auger-Messier M., Lesur O., Marsault E., Dumaine R. and Sarret P.
Effects of C-terminally-modified apelin-13 analogs on cardiovascular function
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada.
46. *Nepveu-Traversy M.E., Morissette S., Boudreault P.L., Besserer-Offroy É., Kirby K., Longpré J.M., Gendron F.P., Breton B., Marsault E., Gaudreau S, and Sarret P.
Chicken antibodies engineered to target the 3D structure of extracellular loops of GPCRs
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada.
45. *Midavaine E., Brouillette R., Besserer-Offroy É., Mona C., Jacobi A., Rose S., Belkhe M., Longpré J.M. and Sarret P.
Targeting the CCL-CCR2 chemokine axis in bone cancer pain: Uncovering analgesic efficacy using non-classical pharmacological approaches
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada.
44. *Brouillette R., Besserer-Offroy É., Mona C., Lavenus S., Côté J., Soubie M., Longpré J.M., Leduc R., Grandbois M., Marsault E. and Sarret P.
Allosteric modulation of the neurotensin 1 receptor by a series of cell-penetrating pepducins targeting the first intracellular loop
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada.
43. *Vivancos M., Fanelli R., Orliaguet M., Floquet N., Côté J., Besserer-Offroy É., Murza A., Longpré J.M., Thomas, J.B., Martinez J., Cavelier F. and Sarret P.
Preferentially targeting the NTS2 receptor: a promising avenue for the development of new neurotensinergic analgesic compounds
18th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 19th-21st, 2017; Ottawa, Canada.
42. *Mona C., Besserer-Offroy É., Cabana J., Leduc R., Lavigne P., Heveker N., Marsault É. and Escher E.
Design, Synthesis, and Biological Evaluation of CXCR4 Ligands
25th American Peptide Symposium; June 17th-22th, 2017; Orlando, USA.
41. *Sousbie M., Besserer-Offroy É., Brouillette R., Longpré J.M., Sarret P., Leduc R. and Marsault E.
Rational design of neurotensin 8-13 macrocyclic peptidic analogues. Conformational investigation and hit discovery
25th American Peptide Symposium; June 17th-22th, 2017; Orlando, USA.
40. *Nepveu-Traversy M.E., Morissette S., Boudreault P.L., Besserer-Offroy É., Kirby K., Longpré J.M., Gendron F.P., Breton B., Marsault E., Gaudreau S, and Sarret P.
Characterization of chicken antibodies targeting the 3D structure of the second extracellular loop of the neurotensin receptor type 1
14th Annual Protein and Antibody Engineering Summit, PEGS; May 1st-4th, 2017; Boston, USA.
39. *Côté J., Besserer-Offroy É., Murza A., Belleville K., Eiselt E., Larocque A., Régina A., Longpré J.M., Demeule M. and Sarret P.
Improving blood-brain barrier penetration to convert neurotensin bioactive peptides into painkillers
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA.
38. *Brouillette R., Mona C., Besserer-Offroy É., Lavenus S., Côté J., Sousbie M., Longpré J.M.*, Leduc R., Grandbois M., Marsault E. and Sarret P.
Deciphering the cellular and physiological actions of cell-penetrating pepducins affecting NTS1 signaling
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA.
37. *Vivancos M., Fanelli R., Orliaguet M., Côté J., Besserer-Offroy É., Murza A., Longpré J.M., Thomas, J.B., Martinez J., Cavelier F. and Sarret P.
Characterization of new stable NTS2-selective neurotensin analogs
Neuroscience 2016 (46th Annual Meeting of the Society for Neuroscience); November 12th-16th, 2016; San Diego, USA.
36. *Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault E.
Rational design of neurotensin 8-13 macrocyclic peptidic analogues. Conformational investigation and hit discovery
17th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 13th-15th, 2016; Chicago, USA.
35. *Murza A., Sainsily X., Coquerel D., Côté J., Marx, P., Besserer-Offroy É., Longpré J.M., Lesur O., Auger-Messier M., Sarret P. and Marsault E.
Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions
17th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 13th-15th, 2016; Chicago, USA.
34. Mona C., Besserer-Offroy É., Cabana J., Leduc R., Lavigne P., Heveker N., Marsault É. and *Escher E.
Agonists-antagonist transition in CXCR4 ligands
Annual Meeting of the Canadian Society of Pharmacology and Therapeutics; September 19th-21st, 2016; Vancouver, Canada. 
33. *Fanelli. R., Floquet N., Vivancos M., Delort B., Besserer-Offroy É., Longpré J.M., Martinez J., Sarret P and Cavelier F.
NTS1 and NTS2 diversity delineated by molecular modeling drives the synthesis of new selective neurotensin analogues
34th European Peptide Symposium; September 4th-9th, 2016; Leipzig, Germany. 
32. *Cavelier F., Fanelli R., Floquet N., Vivancos M., Besserer-Offroy É., Longpré J.M., Martinez J., and Sarret P.
Molecular modeling, design, and synthesis of new NTS2-selective neurotensin analogues
International Symposium on Regulatory Peptides; July 11th-16th, 2016; Rouen, France. 
31. *Marsault E., Besserer-Offroy É., Bérubé P., Côté J., Murza A., Longpré J.M., Leduc R., Coquerel D., Dumaine R., Auger-Messier M. and Lesur O and Sarret P.
Molecular engineering of apelin to modulate stability, signaling, and cardiovascular functions
International Symposium on Regulatory Peptides; July 11th-16th, 2016; Rouen, France. 
30. *Besserer-Offroy É., Bérubé P., Côté J., Murza A., Longpré J.M., Leduc R., Marsault E., and Sarret P.
C-terminal modifications of apelin-13 lead to β-arrestin-biased analogs lowering blood pressure
29th Annual Canadian Student Health Research Forum; June 7th-9th, 2016; Winnipeg, Canada. 
29. *Marsault E., Murza A., Trân K., Sainsily X., Côté J., Besserer-Offroy É., Longpré J.M., Sarret P., Coquerel D., Dumaine R., Auger-Messier M., and Lesur O.
Modulating the structure of apelin to bias signaling of the APJ receptor: impact and potential in cardiovascular diseases
99th Canadian Chemistry Conference and Exhibition; June 5th-9th, 2016; Halifax, Canada.
28. *Marsault E., Murza A., Besserer-Offroy É., Côté J., Longpré J.M. and Sarret P.
Modulating the apelin receptor signaling with macrocycles
Pacifichem; December 15th-20th, 2015; Honolulu, HI, USA.
27. *Lavenus S., Besserer-Offroy É., Simard É., Leduc R. and Grandbois M.
In depth profiling of AT1 signaling using cell-based and label free surface plasmon resonance: major implication of Gq-independent pathways in cell response
16th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 22nd-24th, 2015; Orangeville, Canada.
26. *Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É.
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling
16th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 22nd-24th, 2015; Orangeville, Canada.
25. *Besserer-Offroy É., Lafrance M., Ouirzane M., Murza A., Longpré J.M., Marsault E., Leduc R., and Sarret P.
β-arrestin-2-biased apelin receptor agonists as novel potent analgesics
Neurosciences 2015 (45th annual meeting of the Society for Neuroscience) October 17th-21st, 2015; Chicago, IL, USA.
[Online Abstract]
24. Vivancos M., Besserer-Offroy É., Brouillette R., René A., Fanelli R., Lafrance M., Tétreault P., Colerette-Tremblay J., Longpré J.M., Martinez J., Cavelier F. and Sarret P.
Site-selective modifications of the neurotensin hexapeptide fragment lead to the generation of highly active and metabolically stable NT(8-13) analogs
Neurosciences 2015 (45th annual meeting of the Society for Neuroscience) October 17th-21st, 2015; Chicago, IL, USA.
[Online Abstract]
23. *Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É.
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling
24th American Peptide Symposium; June 20th-25th, 2015; Orlando, FL, USA.
22. *Mona C., Lefrançois M., Besserer-Offroy É., Leduc R., Heveker N., Marsault É. and Escher E.
CXCR4-induced chemotaxis is not β-arrestin mediated, evidence from synthetic CXCR4 agonists
24th American Peptide Symposium; June 20th-25th, 2015; Orlando, FL, USA.
21. *Sousbie M., Besserer-Offroy É., Longpré J.M., Sarret P., Leduc R. and Marsault É.
Macrocyclic analogues of Neurotensin 8-13: effect of conformational restriction on ligand binding and signaling
98th Canadian Chemistry Conference and Exhibition; June 13th-17th, 2015; Ottawa, Canada.
[Online Abstract Booklet]
20. *Besserer-Offroy É., Brumwell A., Murza A., Longpré J.M., Sarret P. and Leduc R.
Establishing the signaling signature of hNTS1 engaged following endogenous neurotensin-like peptide stimulation
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada.
19. *Besserer-Offroy É., Murza A., Bérubé P., Dinh T., Longpré J.M., Leduc R., Marsault É. and Sarret P.
C-terminal modifications of Apelin-13: generation of new biased analogs and impact on hypotensive effect
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada.
18. *Murza A., Besserer-Offroy É., Bérubé P., Longpré J.M., Sarret P. and Marsault E.
Design, synthesis and exploration of structure-function relationship studies of new macrocyclic derivatives of apelin-13
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada.
17. *Tétreault P., Besserer-Offroy É., Murza A., Parent A., Bérubé P., René A., Dubuc I., Longpré J.M., Beaudet N., Leduc R., Marsault É., Martinez J., Cavelier F. and Sarret P.
Analgesic potency of a new neurotensin analog in different experimental pain models
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada.
16. *Lavenus S., Sainsily X., Simard É., Besserer-Offroy É., Grandbois M. and Leduc R.
Profiling of AT1 and UII signaling using surface plasmon resonance as a cell-based label-free approach
15th Annual Joint Meeting of the Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec; October 2nd-4th, 2014; Bromont, Canada.
15. *Marsault E., Murza, A., Besserer-Offroy É., Bérubé P., Longpré J.M. and Sarret P.
Deciphering the structure-function of apelin with unnatural amino acids and macrocycles.
33rd European Peptide Symposium; September 1st-5th, 2014; Sofia, Bulgary.
14. *Murza A., Besserer-Offroy É., Bérubé P., Parent A., Longpré J.M., Leduc R., Sarret P. and Marsault E.
Design, Synthesis and Structure-Activity Relationship Studies of New Macrocyclic Analogs of Apelin-13
97th Canadian Chemistry Conference and Exhibition; June 1st-5th, 2014; Vancouver, Canada.
[Online Abstract]
13. *Besserer-Offroy É., Tétreault P., Lafrance M., Murza A., René A., Longpré J.M., Cavelier F., Matinez J., Marsault E., Leduc R. and Sarret P.
Deciphering the NTS1 receptor signaling pathways leading to analgesia and hypothermia
Neurosciences 2013 (43rd annual meeting of the Society for Neuroscience) November 9th-13th, 2013; San Diego, CA, USA.
[Online Abstract]
12. *Murza A., Besserer-Offroy É., Lafrance M., Beaudet N., Longpré J.M., Leduc R., Marsault E. and Sarret P.
Incorporation of unnatural amino acids into the C-terminal of apelin-13 : Influence on binding, biased signaling and receptor functions
Neurosciences 2013 (43rd annual meeting of the Society for Neuroscience) November 9th-13th, 2013; San Diego, CA, USA.
[Online Abstract]
11. *Lafrance M., Murza A., Besserer-Offroy É., Longpré J.M., Leduc R., Stroh T., Marsault E., Sarret P.
Impact of the incorporation of unnatural amino acids at the C-terminal end of the Apelin peptide on pain inhibition
8th European Federation of IASP Chapters (EFIC), October 9th-12th, 2013; Florence, Italia.
[Online Abstract Booklet]
10. *Besserer-Offroy É., Demeule M., Beaudet N., Régina A., Tétreault P., Belleville K., Ché C., Larocque A., Lachowicz J., Castaigne J.P., Sarret P.
Use of peptide technology for analgesic brain delivery
23rd American Peptide Symposium; June 22nd-23rd, 2013; Waikoloa, Hawaii, USA.
[Online Abstract Booklet]
9. *Besserer-Offroy É., Tétreault P., Lafrance M., Murza A., René A., Longpré J.M., Cavelier F., Martinez J., Marsault É., Leduc R. and Sarret P.
Deciphering the NTS1 receptor signalling pathways leading to analgesia and hypothermia
XXVIIth GEPROM Symposium; June 12th-13th, 2013; Montréal, Canada.
8. *Murza A., Besserer-Offroy É., Lafrance M., Parent A., Beaudet N., Leduc R., Sarret P. and Marsault E.
Incorporation of unnatural amino acids in Apelin: influence on biased signaling and activity in animal models of pain
96th Canadian Chemistry Conference and Exhibition; May 26th-30th, 2013; Québec, Canada.
[Online Abstract]
7. *Tétreault P., Parent A., Besserer-Offroy É., Murza A., René A., Dubuc I., Beaudet N., Leduc R., Marsault E., Martinez J. Cavelier F. and Sarret P.
Neurotensin receptor-based therapy: Achieving analgesia without opioid-related side effects
Neuroscience 2012 (42nd Annual meeting of the Society for Neuroscience), October 13th-17th, 2012; New Orleans, USA.
[Online Abstract]
6. *Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault E.
Structure/activity relationship and plasma stability studies of apelin’s peptide analogues
32nd European Peptide Symposium; September 2nd-7th, 2012; Athens, Greece.
5. *Lafrance M., Murza A., Besserer-Offroy É., Bossé S., Beaudet N., Leduc R., Stroh T., Marsault E. and Sarret P.
Analgesic effect of Apelin and structural analogs on pain modulation
14th World Congress on Pain (IASP); August 27th-31st, 2012; Milan, Italy.
4. *Tétreault P., Parent A., Besserer-Offroy É., Murza A., René A., Dubuc I., Beaudet N., Leduc R., Marsault E., Martinez J. Cavelier F. and Sarret P.
Pain relief devoid of opioid side effects following central action of a new neurotensin analog
14th World Congress on Pain (IASP); August 27th-31st, 2012; Milan, Italy.
3. *Lafrance M., Murza A., Besserer-Offroy É., Bossé S., Beaudet N., Leduc R., Marsault É. and Sarret P.
Involvement of Apelin in pain modulation
Neuroscience 2011 (41st Annual meeting of the Society for Neuroscience); November 12th-16th, 2011; Washington DC, USA
2. *Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault É.
Structure activity relationship and plasma stability studies of apelin’s peptide analogues
94th Canadian Chemistry Conference and Exhibition; June 5th-9th, 2011; Montréal, Canada.
1. *Murza A., Parent A., Besserer-Offroy É., Tremblay H., Karadereye F., Beaudet N., Leduc R., Sarret P. and Marsault É.
Relation structure/activité et etudes de stabilité plasmatique d’analogues peptidiques de l’Apéline
79è Congrès de l’ACFAS; May 9th-13th, 2011; Sherbrooke, Canada.